Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Esteban Ruiz

Internal Medicine Hudson, FL Medical Doctor

NPI 1740226794 CMS profile 124008

13910 Fivay Rd Ste 15, Hudson, FL 34667

Open in the dashboard

General payments

$10,081

577 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Esteban Ruiz of Hudson, FL is reported in the CMS Open Payments database as having received $10,081 across 577 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $905 42
2024 General $1,296 65
2023 General $1,672 98
2022 General $2,008 115
2021 General $2,268 147
2020 General $814 47
2019 General $1,118 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Esteban Ruiz
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Esteban Ruiz were reported at $905. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Esteban Ruiz Internal Medicine median Middle half National median
2019 $1,118 $159 $48–$570 $163
2020 $814 $119 $33–$402 $114
2021 $2,268 $135 $37–$521 $132
2022 $2,008 $141 $42–$496 $149
2023 $1,672 $149 $45–$519 $160
2024 $1,296 $154 $47–$537 $164
2025 $905 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $980 42 payments
  2. AstraZeneca Pharmaceuticals LP $897 52 payments
  3. AbbVie, Inc. $796 65 payments
  4. Novo Nordisk Inc $699 42 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $653 35 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $544 26 payments
  7. Janssen Pharmaceuticals, Inc $533 34 payments
  8. Pfizer Inc. $526 33 payments
  9. Astellas Pharma US Inc $447 15 payments
  10. Amarin Pharma Inc. $427 37 payments
  11. Other $3,579 196 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,902 574 payments
  2. Education $179 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $843 40 payments
  2. Kerendia $653 35 payments
  3. Ozempic $637 38 payments
  4. VRAYLAR $598 51 payments
  5. RYBELSUS $583 35 payments
  6. FARXIGA $523 32 payments
  7. ELIQUIS $408 26 payments
  8. XARELTO $391 25 payments
  9. Vascepa $386 34 payments
  10. GEMTESA $363 21 payments
  11. Other $6,933 383 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 261 drugs

Part D claims

21,455

Median for Internal Medicine: 777

Drug cost

$1,480,056

Median for Internal Medicine: $73,373

Branded share of claims

22.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 418 $267,402
Ozempic Semaglutide Brand 117 $145,030
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 107 $87,591
Otezla Apremilast Brand 22 $53,677
Jardiance Empagliflozin Brand 56 $45,531
Trulicity Dulaglutide Brand 36 $45,109
Rexulti Brexpiprazole Brand 28 $42,245
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 13 $35,602
Xarelto Rivaroxaban Brand 72 $33,469
Farxiga Dapagliflozin Propanediol Brand 42 $32,398

The 10 drugs with the highest cost, of 261 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$252,264

Of which drugs: $1,845

Medicare patients

312

Average age 77

Services billed

5,628

175 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 47%
Arthritis 46%
Ischemic heart disease 45%
Diabetes 43%
Depression 40%
COPD 35%
Heart failure 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 65 65 $1,424
Injection, methylprednisolone acetate, 1 mg J1010 Office 23 2,240 $234
Injection, methylprednisolone acetate, 80 mg J1040 Office 12 13 $61
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 13 24 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $244
$244 107 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $169
$169 11 —
REXULTI
  • Lundbeck LLC $140
$140 28 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $109
$109 20 —
GEMTESA
  • Sumitomo Pharma America, Inc. $66
$66 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

577 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record